Dr. Reddy's Laboratories Launches Imatinib Mesylate Tablets, USP in the US Market
2 October 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NYSE: RDY) has launched matinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate) Tablets in the United States market approved by the US Food and Drug Administration (USFDA), the company said.
The Gleevec brand and generic had US sales of approximately USD 868m MAT for the most recent twelve months ending in July 2018 according to IMS Health.
Dr. Reddy's Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.
Gleevec is a trademark of Novartis Pharmaceuticals Corp.
Dr. Reddy's is an integrated pharmaceutical company. Through its three businesses, Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include USA, India, Russia and CIS countries, and Europe.